Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary
Tamara Pringsheim, Gregory S. Day, Don B. Smith, et al.
Neurology (2021) Vol. 97, Iss. 20, pp. 942-957
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Tremor in Parkinson’s Disease: From Pathophysiology to Advanced Therapies
Ali Abusrair, Walaa Elsekaily, Saeed Bohlega
Tremor and Other Hyperkinetic Movements (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 42
Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases
Panos Stathopoulos, Marinos C. Dalakas
Neurotherapeutics (2022) Vol. 19, Iss. 3, pp. 691-710
Open Access | Times Cited: 39
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited
Walter Pirker, Regina Katzenschlager, Mark Hallett, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 2, pp. 127-144
Open Access | Times Cited: 39
Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
Martin Regensburger, Chi Wang Ip, Zacharias Kohl, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 847-861
Open Access | Times Cited: 29
Epigenetic modification in Parkinson’s disease
Hao Song, Juanli Chen, Jin Huang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 23
Parkinson disease therapy: current strategies and future research priorities
Fabrizio Stocchi, Daniele Bravi, Aron Emmi, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 12, pp. 695-707
Closed Access | Times Cited: 10
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
Stuart Isaacson, Robert A. Hauser, Rajesh Pahwa, et al.
Clinical Parkinsonism & Related Disorders (2023) Vol. 9, pp. 100212-100212
Open Access | Times Cited: 18
Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease
Joseph Seemiller, Christopher J. Morrow, Jared T. Hinkle, et al.
Movement Disorders Clinical Practice (2024) Vol. 11, Iss. 5, pp. 534-542
Closed Access | Times Cited: 7
Pharmacological PINK1 activation ameliorates Pathology in Parkinson’s Disease models
Nicholas T. Hertz, R Chin, Rishi Rakhit, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 7
Effects of a Resistance Training Protocol on Physical Performance, Body Composition, Bone Metabolism, and Systemic Homeostasis in Patients Diagnosed with Parkinson’s Disease: A Pilot Study
Alessandra Amato, Sara Baldassano, Sonya Vasto, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 20, pp. 13022-13022
Open Access | Times Cited: 23
Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
Joaquim J. Ferreira, Werner Poewe, Olivier Rascol, et al.
Movement Disorders (2022) Vol. 37, Iss. 11, pp. 2272-2283
Open Access | Times Cited: 22
Levodopa‐induced orthostatic hypotension in parkinsonism: A red flag of autonomic failure
Ilaria Cani, Pietro Guaraldi, Giulia Giannini, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 1
Open Access | Times Cited: 14
Rationale and Development of Tavapadon, a D1/D5-Selective Partial Dopamine Agonist for the Treatment of Parkinson’s Disease
Erwan Bézard, David Gray, Rouba Kozak, et al.
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 4, pp. 476-487
Open Access | Times Cited: 13
On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson’s Disease Psychosis
Fernando Pagán, Paul E. Schulz, Yasar Torres‐Yaghi, et al.
CNS Drugs (2024) Vol. 38, Iss. 5, pp. 333-347
Open Access | Times Cited: 5
α-Synuclein triggers cofilin pathology and dendritic spine impairment via a PrPC-CCR5 dependent pathway
Marina I. Oliveira da Silva, Miguel Santejo, Isaac W. Babcock, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 4
Open Access | Times Cited: 5
A review of temporal interference, nanoparticles, ultrasound, gene therapy, and designer receptors for Parkinson disease
Amanda D. Currie, Joshua K. Wong, Michael S. Okun
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Katharina Bolsewig, Eline A.J. Willemse, Pascual Sánchez‐Juan, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease
Noriyuki Miyaue, Haruto Yamamoto, Shuang Liu, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
Journal of Neural Transmission (2025)
Open Access
Amantadine use in the French prospective NS-Park cohort
Margherita Fabbri, Vanessa Rousseau, Jean‐Christophe Corvol, et al.
Journal of Neural Transmission (2024) Vol. 131, Iss. 7, pp. 799-811
Closed Access | Times Cited: 4
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
Daniel G. Di Luca, Nikolai Gil D. Reyes, Susan H. Fox
Drugs (2022) Vol. 82, Iss. 10, pp. 1027-1053
Open Access | Times Cited: 18
Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs
Nbaa Masood, Joohi Jimenez‐Shahed
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 247-266
Open Access | Times Cited: 9
Tratamiento farmacológico de los síntomas motores de la enfermedad de Parkinson: actualización y recomendaciones de un experto
Jaime Kulisevsky
Revista de Neurología (2022) Vol. 75, Iss. S04, pp. S1-S1
Open Access | Times Cited: 14
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
Sara C. Staubo, Ole‐Martin Fuskevåg, Mathias Toft, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 2
Open Access | Times Cited: 8
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa‐Induced Dyskinesia
Elena Espa, Lu Song, Katrine Skovgård, et al.
Movement Disorders (2023) Vol. 38, Iss. 3, pp. 410-422
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top